Company Profile
Summit Therapeutics Stock Price, News & Analysis
- Ticker:
- SMMT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom with U
Stock performance
13.54 USD (+0.07%)
Close
Last updated: August 6, 2026
11.5B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SMMT was little changed and closed at $13.54. No new same-company headline was identified in the current news window.
Company overview
Business overview
Summit Therapeutics is a biopharmaceutical company centered on oncology and the commercial potential of its lead cancer programs. The company has become a market focus because of its high-profile clinical and strategic story.
Geographic Base and Sector Classification
Headquartered in the United Kingdom with U.S. market exposure and listed on NASDAQ, Summit sits in oncology biotechnology.
Business Model Characteristics
Its model is driven by clinical data, partnering, and the possibility of turning a focused oncology program into a major value driver.
Position Within the Biotechnology Landscape
Summit is a high-beta oncology name where data and strategic developments can quickly dominate the valuation.
Future catalysts
Summit Therapeutics's catalysts are ivonescimab development and the next oncology readouts that could keep the PD-1 / VEGF story moving. The company matters most when the clinical data stay ahead of the hype.
Recent news
- 01
- 02
- 03
Summit Therapeutics Announces Closing of $75 Million Rights Offering
Source: Summit Therapeutics
- 04
Summit Therapeutics Publishes Scientific Updates to Corporate Website
Source: Summit Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Summit Therapeutics (SMMT)?
Summit Therapeutics (SMMT) most recently closed at 13.54 USD, a +0.07% move versus the previous session.
What is the market cap of Summit Therapeutics (SMMT)?
Summit Therapeutics currently has a market capitalization of 11.5B USD on BioPharmSignal.
What does Summit Therapeutics do?
Summit Therapeutics is a biopharmaceutical company centered on oncology and the commercial potential of its lead cancer programs. The company has become a market focus because of its high-profile clinical and strategic story.
On which exchange is SMMT stock listed?
Summit Therapeutics (SMMT) is associated with NASDAQ, United Kingdom with U, Biopharma.
What is PD-1?
Summit Therapeutics's catalysts are ivonescimab development and the next oncology readouts that could keep the PD-1 / VEGF story moving.
Which conditions is Summit Therapeutics targeting with PD-1?
Summit Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Summit Therapeutics describe recent progress with PD-1?
Summit Therapeutics's catalysts are ivonescimab development and the next oncology readouts that could keep the PD-1 / VEGF story moving.
What is ivonescimab?
Summit Therapeutics's catalysts are ivonescimab development and the next oncology readouts that could keep the PD-1 / VEGF story moving.